ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vasigrobart

Its studies are mostly in Pulmonary Arterial Hypertension, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Jan 2, 20262 company-led studies, 1 open or runningNext primary completion: Feb 27, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals21 open or runningphase 2since Jan 2, 2026Nov 13, 2023Feb 27, 2028phase 2 · NCT07318597

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2023First study: phase 1 study in Healthy VolunteersFirst studyNCT06137482 · 56 enrolled · New Zealand
  2. Jul 10, 2025Named vasigrobartINNProposed as its International Nonproprietary Name in WHO's List 133 · before, REGN13335
  3. Jan 2, 2026Phase 2 study in Pulmonary Arterial HypertensionPhase 2 reachedNCT07318597 · 99 planned · United States, Australia, Belgium and more

Ahead

  1. Feb 27, 2028Primary completion: phase 2 study in Pulmonary Arterial HypertensionNCT07318597

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07318597Pulmonary Arterial Hypertension · United States, Australia, Belgium and more2RecruitingFeb 27, 202899
NCT06137482Healthy Volunteers · New Zealand1CompletedFeb 11, 202556

How it is read

Names in the registry

  • “REGN13335”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.